| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Panobinostat | FIMM | pan-cancer | AAC | 0.028 | 0.8 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.04 | 0.8 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |